



Genetic Engineering & Biotechnology News: Heart Disease May Be Treatable with HDAC6 Inhibitor, Preclinical Data Suggests

July 11, 2022

Tenaya's preclinical study for dilated cardiomyopathy, published in July 2022, is detailed in this article from GEN. The study identified the HDAC6 inhibitor as a target for the potential treatment of DCM.

[Read More](#)